ProfileGDS5678 / 1452289_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 73% 73% 77% 71% 74% 73% 75% 72% 72% 73% 75% 76% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.8857975
GSM967853U87-EV human glioblastoma xenograft - Control 24.706473
GSM967854U87-EV human glioblastoma xenograft - Control 34.6767873
GSM967855U87-EV human glioblastoma xenograft - Control 45.4326977
GSM967856U87-EV human glioblastoma xenograft - Control 54.5009471
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7406474
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.6935973
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0091875
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6477572
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.6687572
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6689773
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9934975
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0770676
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.7052173